Research Article
Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients
Table 5
Adverse events, frequency, duration, disutility, and costs during trabectedin and ifosfamide treatment.
| Adverse events | Frequency of patients (%) | Average duration (days) | Disutility value | Source | QALY loss | Cost per event | Source† | Total costs | Trabectedin | Ifosfamide | Trabectedin | Ifosfamide | Trabectedin | Ifosfamide | Trabectedin | Ifosfamide |
| Fatigue and asthenia | 2.1 | 2.2 | 5.0 | 5.0 | 0.216 | [12] | 0.00006 | 0.00007 | €153 | [13] | €3 | €3 | Nausea | 1.0 | 7.0 | 10.0 | 10.0 | 0.295 | [12] | 0.00008 | 0.00056 | €1,464 | [13] | €15 | €120 | Vomiting | 2.1 | 5.3 | 7.5 | 7.5 | 0.295 | [12] | 0.00013 | 0.00032 | €1,464 | [13] | €31 | €78 | Anaemia | 5.3 | 9.6 | 5.0 | 5.0 | 0.098 | [14] | 0.00007 | 0.00013 | €1,864 | [15] | €99 | €179 | Neutropenia | 14.9 | 39.0 | 7.5 | 5.0 | 0.124 | [16] | 0.00038 | 0.00066 | €1,329 | [15] | €198 | €518 | Febrile neutropenia | 4.3 | 19.7 | 12.5 | 13.0 | 0.124 | [16] | 0.00018 | 0.00087 | €2,919 | [15] | €6 | €575 | Thrombocytopenia | 13.0 | 6.1 | 8.5 | 1.0 | 0.089 | [17] | 0.00027 | 0.00001 | €3,503 | [15] | €445 | €214 | Elevation of liver enzymes | 44.7 | 0.0 | 3.0 | 0.0 | 0.089 | # | 0.00033 | — | €153 | [13] | €68 | — | Alopecia | 0.0 | 8.3 | 0.0 | 36.0 | 0.094 | [16] | — | 0.00077 | €512 | [18] | — | €42 | Neurotoxicity | 0.0 | 5.7 | 1.0 | 1.0 | 0.195 | [12] | — | 0.00003 | €1,650 | [13] | — | €94 | Acute renal failure | 0.0 | 1.8 | 0.0 | 16.0 | 0.124 | [19] | — | 0.00010 | €1,593 | [20] | — | €29 | Catheter-related infection | 2.1 | 0.1 | 3.0 | 0.0 | 0.161 | [17] | 0.00003 | — | €5,920 | [21] | €124 | €6 | | | | | | Total QALY loss | 0.00153 | 0.00352 | Total costs | €1,119 | €1,841 |
|
|
Translated to Dutch utilities; †translated to 2018 costs in euro’s; #assumed similar to thrombocytopenia. |